Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hospital study tracks deadly fungus and a possible predictor of patient outcomes

NCT ID NCT07621263

Knowledge-focused Sponsor: Hospital H+ Queretaro Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study at Hospital H+ Querétaro looked at 150 patients with suspected or confirmed invasive aspergillosis, a serious fungal infection. Researchers measured a substance called galactomannan in lung fluid samples to see if higher levels were linked to worse outcomes like death or longer hospital stays. The study also tracked how often the infection occurred over different seasons and years. The goal was to better understand the infection and see if this biomarker can help predict patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Mar 2022

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population comprises both pediatric and adult patients who sought medical care at Hospital H+ Querétaro and presented with either a clinical suspicion or a confirmed diagnosis of invasive aspergillosis. Participants were identified through a review of hospital clinical records, specifically including those who underwent diagnostic evaluation by means of bronchoalveolar lavage during their hospitalization.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who underwent galactomannan determination testing in bronchoalveolar lavage (BAL) samples * Tests performed during the period from March 2022 to March 2026. Exclusion Criteria: * Patients with galactomannan tests performed outside the established period (March 2022 to March 2026). * Galactomannan tests performed using serum samples.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Invasive aspergillosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

invasive aspergillosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Invasive aspergillosis

Contacts and locations

Locations

  • Hospital H+

    Querétaro City, Querétaro, 7600, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.